Publicação
The extreme value Birnbaum-Saunders model, its moments and an application in biometry
| Resumo: | The Birnbaum-Saunders (BS) model is a life distribution that has been largely studied and applied. Recently, a new version of the BS distribution based on extreme value theory has been introduced, which is named extreme value Birnbaum-Saunders (EVBS) distribution. In this article, we provide some further details on the EVBS models that can be useful as a supplement to the already existing results. We use these models to analyze real survival time data of patients treated with alkylating agents for multiple myeloma. This analysis allow us to show the adequacy of these new statistical distributions and identify them as models useful for medical practitioners in order to obtain a prediction of the survival times of these patients and evaluate changes in the dose of their treatment. |
|---|---|
| Autores principais: | Gomes, M. Ivette |
| Outros Autores: | Ferreira, Marta Susana; Leiva, Víctor |
| Assunto: | Extreme value theory Parametric modelling Survival data |
| Ano: | 2012 |
| País: | Portugal |
| Tipo de documento: | artigo |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Universidade do Minho |
| Idioma: | inglês |
| Origem: | RepositóriUM - Universidade do Minho |
| Resumo: | The Birnbaum-Saunders (BS) model is a life distribution that has been largely studied and applied. Recently, a new version of the BS distribution based on extreme value theory has been introduced, which is named extreme value Birnbaum-Saunders (EVBS) distribution. In this article, we provide some further details on the EVBS models that can be useful as a supplement to the already existing results. We use these models to analyze real survival time data of patients treated with alkylating agents for multiple myeloma. This analysis allow us to show the adequacy of these new statistical distributions and identify them as models useful for medical practitioners in order to obtain a prediction of the survival times of these patients and evaluate changes in the dose of their treatment. |
|---|